- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
437
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
437 companies
Quince Therapeutics
Market Cap: US$87.0m
A biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
QNCX
US$1.63
7D
1.2%
1Y
108.6%
Equillium
Market Cap: US$85.7m
A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
EQ
US$1.40
7D
-6.7%
1Y
77.2%
Context Therapeutics
Market Cap: US$85.6m
A biopharmaceutical company, develops products for the treatment of solid tumors.
CNTX
US$0.90
7D
-9.7%
1Y
-51.2%
BioStem Technologies
Market Cap: US$85.1m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$5.08
7D
2.4%
1Y
-50.9%
XBiotech
Market Cap: US$84.8m
A biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases.
XBIT
US$2.69
7D
-2.5%
1Y
-59.9%
Kalaris Therapeutics
Market Cap: US$84.7m
A clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.
KLRS
US$4.77
7D
8.7%
1Y
n/a
ALX Oncology Holdings
Market Cap: US$83.0m
A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
ALXO
US$1.79
7D
64.2%
1Y
-4.3%
Vaxart
Market Cap: US$82.2m
A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States.
VXRT
US$0.36
7D
-6.5%
1Y
-55.4%
X4 Pharmaceuticals
Market Cap: US$80.2m
A biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
XFOR
US$3.38
7D
4.3%
1Y
-82.9%
OKYO Pharma
Market Cap: US$79.5m
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
OKYO
US$2.22
7D
7.2%
1Y
122.0%
Metagenomi
Market Cap: US$78.4m
A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
MGX
US$2.30
7D
7.5%
1Y
12.7%
PMV Pharmaceuticals
Market Cap: US$77.9m
A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.
PMVP
US$1.40
7D
13.8%
1Y
-5.7%
Sol-Gel Technologies
Market Cap: US$77.4m
Together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally.
SLGL
US$27.99
7D
5.4%
1Y
294.2%
Acumen Pharmaceuticals
Market Cap: US$76.9m
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
ABOS
US$1.48
7D
12.1%
1Y
-39.1%
Sutro Biopharma
Market Cap: US$74.3m
Operates as a oncology company.
STRO
US$0.87
7D
-4.0%
1Y
-75.1%
Repare Therapeutics
Market Cap: US$74.1m
A clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States.
RPTX
US$1.67
7D
-5.4%
1Y
-52.3%
Adicet Bio
Market Cap: US$71.2m
A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
ACET
US$0.84
7D
3.5%
1Y
-40.1%
Artiva Biotherapeutics
Market Cap: US$70.3m
A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
ARTV
US$3.01
7D
26.5%
1Y
-77.4%
Unicycive Therapeutics
Market Cap: US$68.0m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$3.74
7D
-8.6%
1Y
-8.8%
MediciNova
Market Cap: US$61.3m
A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
MNOV
US$1.24
7D
0%
1Y
-34.4%
Clene
Market Cap: US$60.9m
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
CLNN
US$5.88
7D
-7.0%
1Y
28.6%
MariMed
Market Cap: US$57.1m
Engages in cultivation, production, and selling of branded cannabis products in the United States and internationally.
MRMD
US$0.14
7D
0.4%
1Y
-18.0%
Celularity
Market Cap: US$55.3m
A regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases.
CELU
US$2.04
7D
-6.8%
1Y
-32.0%
ImmuCell
Market Cap: US$54.8m
An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.
ICCC
US$6.05
7D
6.8%
1Y
67.5%
Hyperion DeFi
Market Cap: US$54.7m
An ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States.
HYPD
US$8.46
7D
-31.1%
1Y
-77.2%
Cue Biopharma
Market Cap: US$54.4m
A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.
CUE
US$0.69
7D
-5.5%
1Y
52.0%
PolyPid
Market Cap: US$54.0m
A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
PYPD
US$3.37
7D
-3.7%
1Y
-6.4%
INmune Bio
Market Cap: US$51.8m
A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.
INMB
US$2.03
7D
3.0%
1Y
-59.1%
Earth Science Tech
Market Cap: US$51.2m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.17
7D
-9.1%
1Y
12.9%
Veru
Market Cap: US$50.5m
A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).
VERU
US$3.59
7D
0.6%
1Y
-53.7%
Actinium Pharmaceuticals
Market Cap: US$50.5m
Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
ATNM
US$1.59
7D
-3.6%
1Y
-11.2%
PDS Biotechnology
Market Cap: US$49.8m
A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.
PDSB
US$1.03
7D
-10.4%
1Y
-67.1%
Rafael Holdings
Market Cap: US$49.5m
Primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.
RFL
US$1.36
7D
-16.0%
1Y
-31.0%
Acrivon Therapeutics
Market Cap: US$49.1m
A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
ACRV
US$1.54
7D
-7.8%
1Y
-78.8%
Inotiv
Market Cap: US$48.8m
Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally.
NOTV
US$1.36
7D
-6.2%
1Y
-11.7%
Barinthus Biotherapeutics
Market Cap: US$48.0m
A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.
BRNS
US$1.21
7D
9.5%
1Y
0.8%